News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Veloxis Pharma (VELO) Increases Share Capital In Connection With Exercise Of Warrants



9/12/2017 11:19:13 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Company Announcement no. 18/2017

 

To: NASDAQ Copenhagen A/S                                      Copenhagen, Denmark, 12 September 2017

  

Veloxis Increases Share Capital in Connection with Exercise of Warrants

 

Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by 1,500,000 new shares with a nominal value of DKK 0.10 each corresponding to nominally DKK 150,000 as a consequence of the exercise of warrants by former employees of the Company granted under the Company's warrant program.

As a result of the employee’s investment in the Company, proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 531,410.

The subscription price for the new shares is DKK 0.35 per share of nominally DKK 0.10 (with regard to 859,000 shares) and DKK 0.36 per share of nominally DKK 0.10 (with regard to 641,000 shares).

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 171,099,363.10 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

 

For more information, please contact:

Craig A. Collard            

President & CEO                      

Phone: +1 919 591 3090                     

Email: cac@veloxis.com                      

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES